ArticleInfection and immunity2002
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 83 citations in OpenAlex.
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Methods of Cryptococcal Polysaccharide Analysis Using ELISA.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Antibodies to Combat Fungal Infections: Development Strategies and Progress.Microorganisms · 2023Review
- Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.Immunological reviews · 2023Review
- Immunotherapies against human bacterial and fungal infectious diseases: A review.Frontiers in medicine · 2023Review
- Article
- Genome-scale CRISPR screening reveals that C3aR signaling is critical for rapid capture of fungi by macrophages.PLoS pathogens · 2022Article
- Transcriptional Profiles Elucidate Differential Host Responses to Infection withJournal of fungi (Basel, Switzerland) · 2022Article
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020Review
- Combination Immunotherapy with Passive Antibody and Sulfasalazine Accelerates Fungal Clearance and Promotes the Resolution ofInfection and immunity · 2020Article
- PNAG-specific equine IgGVaccine · 2019Article
- Humoral immune responses to infection: common mechanisms and unique strategies to combat pathogen immune evasion tactics.Current opinion in immunology · 2018Review
- Virulence Factors as Targets for Anticryptococcal Therapy.Journal of fungi (Basel, Switzerland) · 2016Review
- Intravascular clearance of disseminating Cryptococcus neoformans in the brain can be improved by enhancing neutrophil recruitment in mice.European journal of immunology · 2016Article
- Cryptococcal therapies and drug targets: the old, the new and the promising.Cellular microbiology · 2016Review
- Real-Time Imaging of Interactions of Neutrophils with Cryptococcus neoformans Demonstrates a Crucial Role of Complement C5a-C5aR Signaling.Infection and immunity · 2016Article
- The protective role of immunoglobulins in fungal infections and inflammation.Seminars in immunopathology · 2015Review
- B cells and antibodies in the defense against Mycobacterium tuberculosis infection.Immunological reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Passive administration of monoclonal antibodies (MAbs) to the capsular polysaccharide of Cryptococcus neoformans can alter the course of infection in mice. In a murine model of cryptococcal infection, immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch variants of the anti-capsular 3E5 MAb prolong the survival of lethally infected mice, whereas the 3E5 IgG3 MAb does not protect and in some cases enhances infection, shortening the life spans of infected mice. We examined the role of complement component C3 in Ab-mediated protection by determining the efficacy of the four mouse IgG subclasses against C. neoformans in mice genetically deficient in factor C3 as well as mice acutely depleted of C3. Similar to other complement-deficient animal models, C3(-/-) mice and mice depleted of C3 by cobra venom factor were more susceptible to C. neoformans infection than control mice, providing further evidence that complement is important in the host defense against the fungus. In the absence of C3, all IgG isotypes prolonged the lives of mice infected with C. neoformans, indicating that protection by IgG does not require the complement pathways. Furthermore, we observed protection with IgG3 in the complement-deficient mice, suggesting that complement is involved in the lack of protection observed with IgG3 in other mouse models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.